Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Efgartigimod PH20 SC in Primary Sjogren's Disease-Associated Dryness
jRCT2071250042Phase 2Active, not recruiting
- Sponsor
- argenx
- Start
- Aug 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing Efgartigimod PH20 SC with Placebo PH20 SC (2 arms). Primary endpoint: Change from baseline in ESSPRI-dryness at week 24. Started Aug 2025; status: active, not recruiting.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on jRCT2071250042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250042.